Maxim analyst Jason McCarthy raised the firm’s price target on Vertex Pharmaceuticals to $400 from $325 and keeps a Buy rating on the shares. The company’s Q1 results exceeded expectations, and its Exa-Cel may be the "next blockbuster" as the largest and most significant of Vertex’ near-term pipeline opportunities, the analyst tells investors in a research note. With the BLA submission completed, Maxim is lowering its sales risk adjustment for exa-cel, the firm added.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $363 from $344 at Bernstein
- Vertex Pharmaceuticals price target raised to $315 from $299 at RBC Capital
- Vertex Pharmaceuticals price target raised to $456 from $341 at Truist
- Vertex Pharmaceuticals price target raised to $350 from $330 at TD Cowen
- Vertex Pharmaceuticals price target raised to $340 from $300 at Stifel
